• LOGIN
  • SUBSCRIBE
  • FREE E-Newsletter/Product Bulletins

Cath Lab Digest

  • Follow us on
  • Home
  • About Us
    • Privacy Policy/Copyright
    • About VDM
  • Issues
    • Current Issue
    • Issue Archives
  • Editor's Update
  • Advertise
  • Reprints
  • Authors
    • Author Instructions
    • Submission Portal
  • Reviewers
  • Contact

Search

Controversies in the Management of Carotid Artery Disease

  • Wed, 10/26/11 - 9:41am
  • 1077 reads
  • 0 comments

The advent of best medical treatment and advances in carotid artery stenting has created equipoise for surgical versus medical/endovascular management of carotid artery disease. Most vascular specialists agree that symptomatic carotid stenosis >70% needs carotid endarterectomy unless those patients are too high-risk for surgery. The controversies exist for asymptomatic carotid artery disease of >60%. The old recommendations based on ACAS trial are outdated. Vascular physicians agree that asymptomatic carotid artery stenosis of >80% will need carotid artery revascularization. However few believe that medical treatment alone should suffice, especially in females and the elderly. Some data from clinical trials show that the best medical treatment patients with carotid artery stenosis can have stroke if there is an unstable plaque. Patterns with “hits” on transcranial Doppler during the follow-up had higher incidence of stroke or TIA.

Several opportunities arise as potential projects for research to diagnose those at risk for stroke with asymptomatic carotid artery disease:

  1. Use of small nitinol wire-based heat probe to check the temperature of the plaque. If the plaque is unstable, those patients will need treatment or continuation of medical treatment. Such technology is available in coronary lesion evaluation as a research method.
  2. Miniaturized 24 H transcranial Doppler that the patient can take home. If the Doppler shows increased hits, then the patient needs carotid revascularization.
  3. Advanced MRI and CT that can characterize a vulnerable plaque with molecular imaging.

We believe that advances in medical treatment, especially statins, will reduce the need for carotid artery revascularizations especially in asymptomatic patients.

image description image description
Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of HMP Communications, the editorial staff, or any member of the editorial advisory board. HMP Communications is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this journal is not a warranty, endorsement or approval of the products or services advertised or of their effectiveness, quality or safety. HMP Communications disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.


Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

More information about formatting options

Image CAPTCHA
Enter the characters shown in the image.

  • Advertise your Job Here
    For information on posting classified ads, please contact:
    Tara Fields, Classified Sales Manager
    (800) 237-7285, ext. 259

vdm Blogs

EVAR found superior to Open AAA Repair for long-term survival in Medicare patients: Another nail in open surgery’s coffin?

Frank J Criado MD FACS FSVM

Aneurysms and Cancer: Which comes first in the endovascular era?

Ross Milner MD FACS

What is the best therapy when we compare current data for revascularization of the SFA?

Lawrence A. Garcia MD

When a Patient Presents with an Ulcer, Take a Careful History

Richard R. Heuser MD FACC FACP FESC FSCAI

Long-term results with bare-metal LifeStent in the SFA: Is this bad news for DES technologies?

Frank J Criado MD FACS FSVM
more »

Vascular Newswire

  • Medtronic Nets New Indications for Resolute Integrity Drug-Eluting Stent in Europe
    Thu, 05/17/12 - 10:22am
  • Abbott's XIENCE PRIME and XIENCE V Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
    Wed, 05/16/12 - 9:26am
  • Hospital Mortality Rates for Cardiovascular Revascularization Patients Varies Significantly by State
    Tue, 05/15/12 - 9:31am
  • Boston Scientific Announces CE Mark and European Launch of Innova Self-expanding Bare-metal Stent System
    Mon, 05/14/12 - 12:07pm
more »

Clinical Events Calendar

  • EuroPCR 2012
    Tue, 05/15/2012 - Fri, 05/18/2012
    Paris, France
  • International Vein Congress (IVC) 2012
    Thu, 05/31/2012 - Sun, 06/03/2012
    Miami Beach, FL, United States
  • New Cardiovascular Horizons (NCVH)
    Wed, 06/06/2012 - Sat, 06/09/2012
    New Orleans, LA, United States
more »

Poll

The current focus to decrease the profile size of aortic stent-grafts: :
REVIEW OUR OTHER Cardiology BRANDS

Our other resources for healthcare professionals.

HMP Communications © 2012 HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. ©2012 HMP Communications